Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis (Q33436247)

26 July 2017

title

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis (English)

1 reference

26 July 2017

1 reference

A Hochhaus

0 references

U Platzbecker

1 reference

26 July 2017

R F Schlenk

1 reference

26 July 2017

F Stegelmann

1 reference

26 July 2017

A Reiter

1 reference

26 July 2017

E Jost

1 reference

26 July 2017

N Gattermann

1 reference

26 July 2017

H Hebart

1 reference

26 July 2017

C Waller

1 reference

26 July 2017

P Schafhausen

1 reference

26 July 2017

I W Blau

1 reference

26 July 2017

W Verbeek

1 reference

26 July 2017

F H Heidel

1 reference

26 July 2017

M Werner

1 reference

26 July 2017

H Kreipe

1 reference

26 July 2017

V Teleanu

1 reference

26 July 2017

A Benner

1 reference

26 July 2017

H Döhner

1 reference

26 July 2017

M Grießhammer

1 reference

26 July 2017

K Döhner

1 reference

26 July 2017

publication date

24 October 2016

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

889-895

1 reference

The evolution of thalidomide and its IMiD derivatives as anticancer agents

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

A phase-2 trial of low-dose pomalidomide in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.299

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

21 January 2018

1 reference

12 December 2020

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

1 reference

12 December 2020

Phase1/-2 study of Pomalidomide in myelofibrosis

1 reference

12 December 2020

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

12 December 2020

DNMT3A mutations in myeloproliferative neoplasms

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

What are RBC-transfusion-dependence and -independence?

1 reference

12 December 2020

Profile of pomalidomide and its potential in the treatment of myelofibrosis

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2016.299

1 reference

Dimensions Publication ID

26 July 2017

1025806578

0 references

1 reference